Mechanical circulatory and respiratory support /

Mechanical Circulatory and Respiratory Support, Second Edition, continues to provide a comprehensive overview of the past, present and future development of mechanical circulatory and respiratory support devices. This new edition provides an update on the field while also introducing new elements wi...

Full description

Saved in:
Bibliographic Details
Other Authors: Gregory, Shaun D. (Editor), Stephens, Andrew F. (Editor), Heinsar, Silver (Editor), Arens, Jutta (Editor), Fraser, John F. (Editor)
Format: Electronic eBook
Language:English
Published: London : Academic Press, [2025]
Edition:Second edition.
Subjects:
Online Access:ScienceDirect
Tags: Add Tag
No Tags, Be the first to tag this record!
Table of Contents:
  • Front Cover
  • Mechanical Circulatory and Respiratory Support
  • Copyright Page
  • Contents
  • List of contributors
  • Preface
  • Acknowledgments
  • 1 Before the device
  • 1 Descent into heart and lung failure
  • Introduction
  • Cardio-circulatory pathophysiology
  • Cardiogenic shock-the primum movens for temporary mechanical circulatory support
  • Heart failure
  • Classification
  • Right ventricular dysfunction
  • Pulmonary hypertension secondary to left heart disease
  • Right heart failure
  • Grading heart failure
  • Defining and recognizing Stage D
  • Heart failure with preserved ejection fraction and heart failure with mildly reduced ejection fraction
  • Respiratory pathophysiology
  • The oxygen cascade
  • Causes of respiratory failure
  • Asthma
  • Acute respiratory distress syndrome
  • Treatment options
  • COVID-19-associated acute respiratory distress syndrome
  • Conclusion
  • References
  • 2 Heart and lung transplantation
  • Introduction
  • History of thoracic transplantation
  • Experimental heart transplantation
  • Clinical heart transplantation
  • Experimental lung transplantation
  • Clinical lung transplantation
  • Experimental heart-lung transplantation
  • Clinical heart-lung transplantation
  • Decision-making in thoracic transplantation
  • Recipient evaluation, indications, contradictions for heart and lung transplantation
  • Indications for heart, lung, and heart-lung transplantation
  • Listing for heart transplantation
  • Listing for lung transplantation
  • Interstitial lung disease
  • Chronic obstructive pulmonary disease
  • Cystic fibrosis
  • Listing for heart-lung transplantation
  • Contradictions to heart and lung transplantation
  • Specific contradictions to heart transplantation
  • Specific contradictions to lung transplantation
  • Specific listing indications in heart and lung transplantation.
  • Ventricular assist device infection
  • Cardiogenic shock
  • Lung transplantation and previous thoracic surgery
  • Extracorporeal life support as a bridge to lung transplantation
  • Esophageal dysfunction
  • Retransplantation
  • Multiorgan transplantation
  • The heart and lung donor
  • The effects of brain death on donor heart and lung function
  • Heart and lung donor selection
  • Selection of donor hearts
  • Selection of donor lungs
  • Donor-recipient matching in heart and lung transplantation
  • Donor-recipient size matching
  • Immunological matching
  • Surgical techniques
  • Donor heart and lung procurement
  • Donor heart procurement
  • Lung preservation
  • Donor procurement operation
  • Technique of orthotopic cardiac transplantation
  • Technique of lung transplantation
  • Technique of heart-lung transplantation
  • Immunosuppression
  • Immunosuppression agents
  • T-cell directed therapy
  • Agents targeting signal 1
  • Agents targeting signal 2
  • B-cell directed therapy
  • B-cell targeting
  • Plasma cell targeting
  • Complement inhibition
  • Other targets
  • Agents targeting cytokines
  • Nonspecific cytokine inhibition
  • Specific cytokine inhibition
  • IL-2 receptor antagonist
  • Pooled polyclonal antibodies as immunosuppressive agents
  • Immune globulins
  • Polyclonal antithymocyte globulins
  • Immunosuppressive agents with multiple cellular targets
  • Antiproliferative agents: mTOR inhibitors
  • Antimetabolites
  • Cytotoxic agents as immunosuppressive agents
  • Principles of immunosuppression for heart and lung transplantation
  • Induction therapy
  • Maintenance immunosuppression
  • Treatment of acute rejection in heart and lung recipients
  • Hyperacute rejection
  • Acute rejection
  • Acute cellular rejection after cardiac transplantation
  • Antibody-mediated rejection after cardiac transplantation.
  • Acute cellular rejection after lung transplantation
  • Antibody-mediated rejection after lung transplantation
  • Acute rejection after heart-lung transplantation
  • Chronic lung allograft dysfunction
  • Malignancy
  • Airway complications after lung transplantation
  • Bronchial stenosis
  • Anastomotic necrosis and dehiscence
  • Exophytic granulation tissue
  • Tracheo-bronchomalacia
  • Bronchial fistula
  • Anastomotic infections
  • Cardiac allograft vasculopathy
  • Infection after heart and lung transplantation
  • Other complications after lung transplantation
  • Long-term complications after heart and lung transplantation
  • Survival after heart and lung transplantation
  • Conclusion
  • References
  • 3 Ex-vivo organ support
  • Introduction
  • The metabolic underpinnings of donor heart myocardial injury
  • Alternatives to static cold storage
  • Machine perfusion
  • History
  • The beginning of machine perfusion of the heart
  • Hypothermic oxygenated machine perfusion of donor hearts
  • Normothermic machine perfusion of donor hearts
  • Normothermic machine perfusion
  • Donation after circulatory death
  • Normothermic machine perfusion, nonbeating donor hearts, and warm ischemia
  • Clinical experience with DCD heart transplantation and normothermic machine perfusion
  • Withdrawal protocols
  • Donor considerations
  • Assessment during normothermic machine perfusion
  • Clinical outcomes and future directions
  • Thoracoabdominal normothermic regional perfusion
  • Hypothermic oxygenated machine perfusion
  • Hypothermic preservation solutions
  • Preclinical experience with HOPE
  • Clinical application of HOPE of donor hearts
  • Future directions
  • Conclusion
  • References
  • 2 Types of mechanical circulatory and respiratory support devices
  • 4 Ventricular assist devices: volume displacement pumps
  • Introduction
  • Principle of operation.
  • History of volume-displacement ventricular assist devices
  • Devices
  • Thoratec HeartMate I
  • Thoratec PVAD
  • Thoratec IVAD
  • Abiomed BVS5000
  • Abiomed AB 5000
  • Arrow LionHeart
  • Berlin Heart Excor
  • MEDOs-HIA VAD
  • NIPRO-VAD
  • Novacor LVAS
  • ZEON VAD
  • Advantages and disadvantages
  • Advantages
  • Disadvantages
  • The future of volume displacement pumps
  • Conclusion
  • References
  • 5 Ventricular assist devices: rotary blood pumps
  • Introduction
  • Categorization
  • Pump type
  • Bearing type
  • Clinical application
  • Rotary blood pumps
  • Historical pumps
  • Modern pumps
  • Abbott HeartMate 3 LVAD
  • Abbott CentriMag LVAD
  • Abiomed Impella 5.5
  • Future pumps
  • CH Biomedical-BRIOVAD LVAD
  • Fineheart ICOMS Flowmaker LVAD
  • Procyrion Aortix
  • Shenzhen CorHeart 6 LVAD
  • Sun Medical EVAHEART 2 LVAD
  • Outlook
  • References
  • 6 Total artificial hearts
  • Total artificial hearts
  • Total artificial heart requirements and challenges
  • Origins of the total artificial heart
  • Liotta-Cooley TAH (1969)
  • Akutsu III TAH (1981)
  • JARVIK 7 TAH (1982)
  • Totally implantable technology
  • Sarns-3M TAH
  • Nimbus TAH
  • AbioCor TAH
  • The future of TAH technology
  • Rotary TAHs
  • Dual rotary LVADs as a TAH
  • Single-device rotary TAH
  • Cleveland Clinic CF-TAH (previously known as SmartHeart TAH)
  • BiVACOR TAH
  • Positive displacement
  • SynCardia TAH
  • CARMAT TAH
  • ReinHeart TAH
  • Realheart TAH
  • Conclusion
  • Acknowledgments
  • References
  • 7 Devices for heart failure with preserved ejection fraction
  • Introduction
  • Differences between HFrEF and HFpEF
  • Epidemiology
  • Phenotypes of HFpEF
  • Current clinical management
  • Pharmaceutical therapies
  • Device therapies
  • Therapeutic approaches under development
  • Pharmaceutical therapies
  • Emerging devices
  • Atrial shunt devices
  • Left ventricular expanders.
  • Stimulation therapies
  • MCS devices for HFpEF patients
  • Valveless pulsatile pump (CoPulse)
  • Left atrial assist device
  • Left atrial decompression pump (Synergy)
  • Centrifugal left atrial decompression pump
  • Challenges in MCS device development for HFpEF patients
  • Heart geometry
  • Physiology
  • Experience in device-based HFpEF treatment
  • Summary and future considerations
  • Conclusion
  • References
  • 8 Extracorporeal membrane oxygenation
  • Introduction
  • History of extracorporeal circulation/oxygenation
  • Circuit configuration
  • Considerations for circuit selection
  • Current designs
  • Cannulae
  • Pump
  • Oxygenator
  • Heat exchanger
  • Tubing and connectors
  • Economics and long-term outcomes
  • Center volume
  • Future prospects
  • Technological developments
  • Establishing care standards through robust research networks
  • Conclusion
  • References
  • 3 Implantation and medical management
  • 9 Optimizing the patient and timing the introduction of mechanical circulatory and respiratory support
  • Introduction
  • Early optimization strategies
  • Extracorporeal respiratory support for respiratory failure
  • Acute respiratory failure
  • V-V ECMO for acute respiratory failure
  • Timing of V-V ECMO in acute respiratory failure
  • Outcomes after V-V ECMO for acute respiratory failure
  • ECCO2R for acute respiratory failure
  • Chronic respiratory failure
  • V-V ECMO in decompensated chronic respiratory failure
  • ECCO2R in decompensated chronic respiratory failure
  • ERS as bridge to lung transplantation
  • Extracorporeal respiratory support summary
  • Mechanical circulatory support in cardiac failure
  • Acute cardiac failure
  • V-A ECMO for temporary MCS
  • Percutaneous ventricular assistive devices for temporary MCS
  • Surgically implanted external ventricular assistive devices
  • Timing of MCS for acute cardiac failure.